pone.0261410.s003.pdf (966.75 kB)
Protocol.
journal contribution
posted on 2021-12-23, 18:31 authored by Elena L. Amelina, Stanislav A. Krasovsky, Nina E. Akhtyamova-Givirovskaya, Nataliya Yu. Kashirskaya, Diana I. Abdulganieva, Irina K. Asherova, Ilya E. Zilber, Liliya S. Kozyreva, Lubov M. Kudelya, Natalya D. Ponomareva, Nataliya P. Revel-Muroz, Elena M. Reutskaya, Tatiana A. Stepanenko, Gulnara N. Seitova, Olga P. Ukhanova, Olga V. Magnitskaya, Dmitry A. Kudlay, Oksana A. Markova, Elena V. Gapchenko(PDF)
History
Usage metrics
Categories
Keywords
mean fvc changesgeorge &# 8217expensive medicinal productscompared efficacy endpointsterm symptomatic therapylabel clinical trialanalyses included subgrouplarger comparative studypatients ’ data100 patients registeredsecondary efficacy parameterssimilar mean fevsevere pulmonary impairmentnct04468100 ))severe impairmentefficacy datasetadequate therapystudy supportrandomized studynct04468100 ),nct04468100 ))23 patientsclinical tigerasetreatment groupsubgroup analysissafety parametersrespiratory questionnairegeneric versionfirst biosimilardrug antibodydornase alfacystic fibrosiscomparable drugcomparable amongbody weightbaseline fevalso comparable24 weeks
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC